Depression and anxiety disorders during pegylated interferon treatment in patients with chronic hepatitis B

References

• Niederau C. Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol. 2014;20(33):11595–11617. doi: 10.3748/wjg.v20.i33.11595
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis B. 2015. [Internet] [cited 2016 April]. Available from: http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf
   Google Scholar
• Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6(3):531–561. doi: 10.1007/s12072-012-9365-4
   PubMed Web of Science ®Google Scholar
• Zahiu CD, Rimbas M. Neuropsychiatric side-effects of interferon-alpha treatment: pathophysiology and therapeutic options. Maedica (Buchar). 2014;9(2):121–126.
   Google Scholar
• Zhang Y, Chen B, Wang L, et al. HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review. Rev Esp Enferm Dig. 2016;108(5):263–270.
   Web of Science ®Google Scholar
• Hagiwara S, Nishida N, Kudo M. Antiviral therapy for chronic hepatitis B: combination of nucleoside analogs and interferon. World J Hepatol. 2015;7(23):2427–2431. doi: 10.4254/wjh.v7.i23.2427
   Web of Science ®Google Scholar
• Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology. 2016;150(1):134–144.e10. doi: 10.1053/j.gastro.2015.09.043
   PubMed Web of Science ®Google Scholar
• Bernstein D, Kleinman L, Barker CM, et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002;35(3):704–708. doi: 10.1053/jhep.2002.31311
   PubMed Web of Science ®Google Scholar
• Leutscher PD, Lagging M, Buhl MR, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 2010;52(2):430–435. doi: 10.1002/hep.23699
   Web of Science ®Google Scholar
• Lotrich FE. Psychiatric clearance for patients started on interferon-alpha-based therapies. Am J Psychiatry. 2013;170(6):592–597. doi: 10.1176/appi.ajp.2013.12121572
   Web of Science ®Google Scholar
• Marcellin P, Lau GK, Zeuzem S, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int. 2008;28(4):477–485. doi: 10.1111/j.1478-3231.2008.01696.x
   Web of Science ®Google Scholar
• Castera L, Constant A, Henry C, et al. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther. 2006;24(8):1223–1230. doi: 10.1111/j.1365-2036.2006.03107.x
   Web of Science ®Google Scholar
• Martin-Santos R, Diez-Quevedo C, Castellvi P, et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther. 2008;27(3):257–265. doi: 10.1111/j.1365-2036.2007.03568.x
   Web of Science ®Google Scholar
• Sarkar S, Sarkar R, Berg T, et al. Sadness and mild cognitive impairment as predictors for interferon-alpha-induced depression in patients with hepatitis C. Br J Psychiatry. 2015;206(1):45–51. doi: 10.1192/bjp.bp.113.141770
   Web of Science ®Google Scholar
• Koskinas J, Merkouraki P, Manesis E, et al. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis. 2002;20(3–4):284–288. doi: 10.1159/000067682
   Web of Science ®Google Scholar
• Udina M, Castellvi P, Moreno-Espana J, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2012;73(8):1128–1138. doi: 10.4088/JCP.12r07694
   PubMed Web of Science ®Google Scholar
• AlHuthail YR. Comparison of the prevalence of psychiatric co-morbidities in hepatitis C patients and hepatitis B patients in Saudi Arabia. Saudi J Gastroenterol. 2013;19(4):165–171. doi: 10.4103/1319-3767.114514
   Web of Science ®Google Scholar
• Huang YW, Hu JT, Hu FC, et al. Biphasic pattern of depression and its predictors during pegylated interferon-based therapy in chronic hepatitis B and C patients. Antivir Ther. 2013;18(4):567–573. doi: 10.3851/IMP2441
   Web of Science ®Google Scholar
• Williams JB. A structured interview guide for the Hamilton depression rating scale. Arch Gen Psychiatry. 1988;45(8):742–747. doi: 10.1001/archpsyc.1988.01800320058007
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55. doi: 10.1111/j.2044-8341.1959.tb00467.x
   PubMed Web of Science ®Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28–37.
   PubMedGoogle Scholar
• Akdemir A, Turkcapar MH, Orsel SD, et al. Reliability and validity of the turkish version of the Hamilton depression rating scale. Compr Psychiatry. 2001;42(2):161–165. doi: 10.1053/comp.2001.19756
   PubMed Web of Science ®Google Scholar
• Yazici MK, Demir B, Tanriverdi N, et al. [Hamilton anxiety rating scale: interrater reliability and validity study]. Turk Psikiyatri Derg. 1998;9(2):114–117. Turkish.
   Google Scholar
• Zimmerman M, Martinez JH, Young D, et al. Severity classification on the Hamilton depression rating scale. J Affect Disord. 2013;150(2):384–388. doi: 10.1016/j.jad.2013.04.028
   PubMed Web of Science ®Google Scholar
• Rifflet H, Vuillemin E, Oberti F, et al. [Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha]. Gastroenterol Clin Biol. 1998;22(3):353–357. French.
   Google Scholar
• Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7(9):942–947. doi: 10.1038/sj.mp.4001119
   PubMed Web of Science ®Google Scholar
• Cozzolongo R, Porcelli P, Cariola F, et al. Serotonin gene polymorphisms and lifetime mood disorders in predicting interferon-induced depression in chronic hepatitis C. J Affect Disord. 2015;183:90–97. doi: 10.1016/j.jad.2015.04.056
   Web of Science ®Google Scholar
• Felger JC, Haroon E, Woolwine BJ, et al. Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus. Physiol Behav. 2016;166:14–21. doi: 10.1016/j.physbeh.2015.12.013
   PubMed Web of Science ®Google Scholar
• Malek-Ahmadi P, Hilsabeck RC. Neuropsychiatric complications of interferons: classification, neurochemical bases, and management. Ann Clin Psychiatry. 2007;19(2):113–123. doi: 10.1080/10401230701333038
   Google Scholar
• Raison CL, Demetrashvili M, Capuron L, et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19(2):105–123. doi: 10.2165/00023210-200519020-00002
   PubMed Web of Science ®Google Scholar
• Asnis GM, De La Garza R. Interferon-induced depression: strategies in treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(5):808–818. doi: 10.1016/j.pnpbp.2005.03.006
   Web of Science ®Google Scholar
• Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord. 2004;82(2):175–190. doi: 10.1016/j.jad.2004.04.002
   PubMed Web of Science ®Google Scholar
• Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci. 2004;29(1):11–17.
   Web of Science ®Google Scholar
• Cicek IE, Cicek E, Kayhan F, et al. The roles of BDNF, S100B, and oxidative stress in interferon-induced depression and the effect of antidepressant treatment in patients with chronic viral hepatitis: a prospective study. J Psychosom Res. 2014;76(3):227–232. doi: 10.1016/j.jpsychores.2014.01.003
   Web of Science ®Google Scholar
• Baraldi S, Hepgul N, Mondelli V, et al. Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol. 2012;32(4):531–543. doi: 10.1097/JCP.0b013e31825d9982
   PubMed Web of Science ®Google Scholar
• Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004
   PubMed Web of Science ®Google Scholar
• Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–897. doi: 10.1037/0022-006X.56.6.893
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x
   PubMed Web of Science ®Google Scholar